Saying "yes" to obese living liver donors

Liver Transplantation

Volumn 12, Issue 6, 2006, Pages 1012-1016

  Perkins, James D ^a  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEZAFIBRATE; BILIRUBIN;

BILIRUBIN BLOOD LEVEL; BODY MASS; BODY WEIGHT; DISEASE SEVERITY; EXERCISE; FATTY LIVER; HUMAN; LIPID METABOLISM; LIVER FUNCTION TEST; LIVER INJURY; LIVER TRANSPLANTATION; LIVING DONOR; OBESITY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN DIET; PROTHROMBIN TIME; RISK REDUCTION; SHORT SURVEY;

EID: 33745501159     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.20807     Document Type: Short Survey

References (3)

1. Markin RS, Wisecarver JL, Radio SJ, Stratta RJ, Langnas AN, Hirst K, Shaw BW Jr. Frozen section evaluation of donor livers before transplantation. Transplantation 1993;56:1403-1409.
2. Saibara T, Onishi S, Ogawa Y, Yoshida S, Enzan H. Bezafibrate for tamoxifen-induced non-alcoholic steatohepatitis. Lancet 1999;353:1802.
3. Després JP, Golay A, Sjöström L, Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005; 353:2121-2134.